Results 201 to 210 of about 28,422 (269)

Comparative effectiveness of omalizumab in asthma-COPD overlap vs. asthma: a retrospective cohort study. [PDF]

Front Med (Lausanne)
Sun H, Gu Y, Wang Y, Chen L, Guo B, Song X, Song F, Xie S.   +7 more
europepmc   +1 more source

Treatment Challenges in Refractory Urticarial Vasculitis. [PDF]

Clin Cosmet Investig Dermatol
Sun L, Yu Q, Chen X.
europepmc   +1 more source

Early control or gradual relief? Gender-specific real-world insights into omalizumab response in chronic spontaneous urticaria patients. [PDF]

World Allergy Organ J
Preis S, Lisiecki M, Biedermann T, Horster S, Zink A.   +4 more
europepmc   +1 more source

Thyroid autoantibodies predict long-term treatment response in euthyroid chronic spontaneous urticaria: a retrospective cohort study with propensity score matching. [PDF]

Front Med (Lausanne)
Zhuang L, Zhuang C, Jiang H, Su S.
europepmc   +1 more source

Cold Urticaria: its Importance in the Operating Room [PDF]

, 2010
Borbolla, J.M. (J.M.) de la, Gastaminza, G. (Gabriel), Lafuente, A. (A.), Mbongo, C. (C.), Tapies, S. (S.)   +4 more
core  

Considerations for biologics as front-line treatment in allergic diseases. [PDF]

Front Immunol
Kothari A, Hung L, Upton JEM.
europepmc   +1 more source

Omalizumab Combined with Cyclosporine for the Treatment and Management of Refractory Urticarial Vasculitis. [PDF]

Clin Cosmet Investig Dermatol
Chen X, Yu Q, Chang D, Sun L.
europepmc   +1 more source

Emerging Insights into Hereditary Alpha-Tryptasemia in the Context of Mast Cell Disorders: A Greek Case Series. [PDF]

J Pers Med
Koliofotis F, Katrachoura N, Papapostolou N, Taka S, Martinou M, Bouchla A, Papageorgiou SG, Makris M.   +7 more
europepmc   +1 more source

Clinical phenotypes and molecular endotypes of chronic urticaria: Linking clinical expression to underlying immune mechanisms. [PDF]

Asia Pac Allergy
Türk M, Bizjak-Suran M, Can PK, Criado PR, Fluhr JW, Özceker D, Pawankar R, Pyatilova P, Salman A, Sánchez J, Tuncay G, Xiang YK, Yücel MB, Kocatürk E.   +13 more
europepmc   +1 more source

Off-label applications of omalizumab: Current insights and perspectives. [PDF]

World Allergy Organ J
Jaromin A, Wardzyńska A.
europepmc   +1 more source